News

Lisa Swanson, MD: Detailing Infantile Hemangioma

Dr. Elewski hopes that in the future more clinicians will prescribe biologics such as secukinumab and etancercept for the treatment of psoriasis.

FDA Approves Treatment for Rare Blood Disease Polycythemia Vera

Though not all hemangioma last past 10 years old in pediatric patients, some untreated hemangioma are associated with high risk of ulceration.

By Giuliana Grossi

Boni Elewski, MD: Safety and Efficacy of New Psoriasis Therapies

Ropeginterferon Alfa-2b-NJFT (Besremi) is approved by the FDA for the treatment of polycythemia vera regardless of a patient's treatment history.

Lisa Swanson, MD: The Psychology of Pediatric Chronic Skin Conditions

Certain biologics such as infliximab have aided psoriasis patients in the mitigation of symptoms from the COVID-19 virus.

Seemal Desai, MD: The Promise of JAK Inhibitors in Vitiligo Management

Dr. Swanson also details the effects of the COVID-19 pandemic on her practice with the implementation of telemedicine.

Boni Elewski, MD: The Future of Psoriasis Therapy

Dr. Desai says that Janus kinase inhibitors present a new mechanism of action, with effects on cytokine signals that signal inflammation in atopic diseases.

Lisa Swanson, MD: Detailing Therapies for Pediatric Skin Conditions

Dr. Elewski speaks of the safety and efficacy of several new and developing therapies, including bimekizumab treatment which has yet to be approved in the United States.

Saakshi Khattri, MD: Diagnosing Psoriatic Arthritis Early in Psoriasis Patients

Swanson noted the efficacy and safety of dupilumab, which she feels revolutionized patient care.

Seemal Desai, MD: Advancements in Vitiligo Therapies

Dr. Khattri speaks of the benefits of diagnosing the condition early in psoriasis patients, as well as what dermatologists can do before referring a patient to a rheumatologist.

Carl D. Regillo, MD: Key Factors of Faricimab In Neovascular AMD Treatment

New therapies are breaking ground in the world of vitiligo research, which Dr. Desai believes will result in FDA approvals in the coming years.

Rishi P. SIngh, MD: Advances and Challenges in Neovascular AMD Treatment

Dr. Regillo discusses the efficacy and durability of faricimab for wet AMD treatment in TENAYA and LUCERNE, showing noninferiority to aflibercept.

US Patient Access to Ophthalmology Clinical Trial Sites Differs by Regions

Dr. Singh discusses the aging population in ophthalmology care, advances including port delivery systems, and the potential rapid uptake of faricimab in treatment.

Rishi P. SIngh, MD: Durability of Faricimab in Neovascular AMD Treatment

A geographical study shows patients in areas with lower income, education, and higher rates of ophthalmic disease may be a greater distance from a trial site.

Ranibizumab Biosimilar FYB201 Provides Similar Efficacy, Safety in Phase 3 Trial

Dr. Singh discusses results from TENAYA and LUCERNE on faricimab compared to afilbercept in patients with nAMD.

New Model Could Predict Cost of PDR Prevention with Aflibercept

The COLUMBUS-AMD trial suggests the investigative biosimilar could benefit patients newly diagnosed with nAMD.

Deepak Bhatt, MD, MPH: Sotagliflozin Provides Consistent Benefit Across Spectrum of Kidney Function

A cost-based assessment of Protocol W and PANORAMA clinical data suggests diabetic retinopathy may be less costly to prevent than macular edema.

By Patrick Campbell

Paul Sternberg, MD: Perspectives on Step Therapy in Wet AMD Treatment

Deepak Bhatt, MD, MPH, discusses the results of a pooled analysis of the SOLOIST and SCORED trials assessing effects of sotagliflozin based on baseline eGFR among patients included in the trials.

Bevacizumab Formulation Significantly Improves wAMD Vision Versus Ranibizumab in NORSE 2

Dr. Sternberg discusses step therapy in wetAMD treatment and his opinions in favor of its use.

Treat-and-Extend for Anti-VEGF May Provide More Optimal Dosing and Fewer Clinic Visits

Bevacizumab-vikg was associated with statistically significant improvements in patient BCVA scores over a period of 12 months, according to phase 3 findings.

Vorolanib via Durasert Provides Safe Treatment of Wet AMD Through 12 Months

A meta-analysis comparison of dosing regimens for patients with nAMD show little difference in efficacy, but differences in patient involvement in care.

David R. Lally, MD: Analyzing Nascent GA, Intermediate AMD Progression from GATHER1

A phase 1 trial of the investigative drug suggests its promise in a novel strategy of managing patients with retinal fluid.

Gene Therapy ADVM-022 Provides Mixed Efficacy, Safety in Treating DME

Dr. Lally discusses the effect of avacincaptad pegol treatment on the progression of geographic atrophy and intermediate age-related macular degeneration.

Optogenetics Product Provides Safe Treatment Opportunity for Retinitis Pigmentosa Reversal

Findings from the phase 2 INFINITY suggest a more dose-dependent influence on safety outcomes in patients receiving sustained benefit for diabetic macular edema.

Julia A Haller, MD: Facing Challenges and Finding Solutions in Retina

An update from the PIONEER trial shows the combination gene therapy and medical device strategy is safe and tolerable, while providing cases of improved light perception.

Dosing Variability Risk Could Be High With Aflibercept PFS

Dr. Haller discusses issues in diversity and inclusion in retina, but provides avenues for solutions and what needs to come next.

COVID-19 Lockdowns Drove Fewer Anti-VEGF Injections, Worse Vision in Ophthalmic Patients

An AAO 2021 presentation highlighted the industrial design differences that could result in treatment overdoses with pre-filled syringes of aflibercept.